Zuranolone in major depressive disorder: results from MOUNTAIN-a Phase 3, multicenter, double-blind, randomized, placebo-controlled trial.
1. 请及时下载文件确认是否正确, 系统将在 2026-06-18 15:15:20 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
AH Clayton, R Lasser, I Nandy, AJ Sankoh…
The Journal of …, 2023
europepmc.org
Objective: To evaluate the efficacy and safety of zuranolone, an investigational neuroactive steroid and GABA A receptor positive allosteric modulator, in major depressive disorder (MDD). Methods: The phase 3, double-blind, randomized, placebo-controlled MOUNTAIN study enrolled adult outpatients with DSM-5-diagnosed MDD, 17-item Hamilton Depression Rating Scale total score (HDRS-17)≥ 22, and Montgomery-Asberg Depression Rating Scale total score≥ 32. Patients were randomized to treatment with zuranolone 20 mg …
